Swiss Healthtech Stock News

ams-OSRAM (SWX:AMS) is back in focus after divesting non optical sensor businesses and sharpening its push into digital photonics, while consensus EPS estimates for the quarter have been revised sharply higher. See our latest analysis for ams-OSRAM. That sharper focus on digital photonics and the recent EPS estimate upgrade sit against a share price of CHF16.86, with a 90 day share price return of 105.86% and a 1 year total shareholder return of 88.38%, even though the 3 and 5 year total...

Guidance update puts Kardex Holding (SWX:KARN) in focus Kardex Holding (SWX:KARN) issued new earnings guidance for 2026, projecting order and revenue growth in a 15% to 20% range, along with a business update call that drew fresh attention to the stock. See our latest analysis for Kardex Holding. The updated guidance and business call came after a challenging spell for the stock, with the 7 day share price return down 17.46% and the year to date share price return down 22.87%, while the 3...

Nestlé (SWX:NESN) is rolling out a broad turnaround plan under CEO Philipp Navratil, centered on workforce restructuring and a sharper focus on core and high growth brands. The plan includes a global restructuring program affecting 16,000 jobs, alongside portfolio changes such as the divestment of its Chilean water joint venture. The company is also pursuing new acquisitions while negotiating measures in key regions to limit the impact of job reductions. Nestlé, one of the largest global...

Kuros Biosciences (SWX:KURN) has drawn fresh attention after outlining earnings and revenue targets that it expects to outpace the Swiss market, along with projected sales of US$300 million to US$330 million by 2028. See our latest analysis for Kuros Biosciences. At a share price of CHF20.82, Kuros Biosciences has seen short term momentum pick up, with a 1 month share price return of 9.58%, even though the 1 year total shareholder return is down 23.46% after a very large 3 year gain of more...

Temenos share performance snapshot Temenos (SWX:TEMN) has drawn investor attention after a period of weaker recent share performance, with the stock down 1% over the past day, 2% over the past week, and 8% over the past month. See our latest analysis for Temenos. At a share price of CHF67.3, Temenos has seen pressure on short term momentum, with the 90 day share price return down 10.98%, while the 1 year total shareholder return of 7.09% contrasts with longer term 3 and 5 year total...

Cosmo (SWX:COPN) is back in focus after partner Glenmark Specialty S.A. began rolling out Winlevi cream across several European countries, following European Commission approval for treating acne in adults and adolescents. See our latest analysis for Cosmo. Despite the Winlevi rollout and Cosmo presenting at the Jefferies Global Healthcare Conference, the CHF70.5 share price is down 21.93% on a 90 day share price return and 33.11% on a year to date share price return. At the same time, the 1...

What recent trading tells you about Landis+Gyr Group (SWX:LAND) Landis+Gyr Group (SWX:LAND) has drawn attention after a mixed stretch in the stock, with a modest gain over the past month set against declines over the past 3 months and year. See our latest analysis for Landis+Gyr Group. At a share price of CHF48.95, Landis+Gyr Group has seen short term momentum cool, with the 7 day share price return down 6.94% and the 1 year total shareholder return down 9.15%. This points to fading...

As European markets navigate a period of uncertainty marked by economic contractions and fluctuating retail sales, investors are increasingly focused on identifying opportunities that offer attractive valuations. In this context, finding stocks trading below their estimated intrinsic values can be a prudent strategy for those looking to capitalize on potential market inefficiencies.

If you are wondering whether Sandoz Group stock still offers value at current levels, or if the recent run has already priced in the opportunity, this article breaks down what the market might be implying about the company. The stock last closed at CHF 64.60, with returns of 2.7% over the past week, a decline of 3.4% over the past month, 12.9% year to date, and 50.5% over the past year. This performance may catch the eye of investors tracking momentum and changing risk perceptions. Recent...

Why this new loan matters for Idorsia shareholders Idorsia (SWX:IDIA) has agreed a senior secured term loan facility of up to CHF 250 million with funds managed by Pharmakon Advisors, a move that directly reshapes the company’s near term debt profile. The first CHF 150 million tranche will refinance Idorsia’s existing New Money Facility, removing upcoming maturities linked to the CHF 105 million already drawn and extending breathing room beyond the May 2027 deadline. See our latest analysis...

The aluminum sector is suddenly in the spotlight as tariffs, supply disruptions in the Middle East, and shifting trade routes push prices to a four year high and reroute flows of metal across borders. For investors, this mix of pressure and opportunity can quickly separate the strongest producers from the rest. This article highlights 3 aluminum stocks from our screener that are directly exposed to these developments, from soaring US Midwest premiums to a surge in Canadian exports to Europe...

Roche Holding (SWX:ROP) and Nurix Therapeutics announced a global collaboration to co-develop and co-commercialise bexobrutideg, a novel BTK degrader. The partnership targets hematology, immunology, and neurology indications, aiming to address resistance seen with existing BTK inhibitors. The deal expands Roche's exposure to targeted protein degradation therapies and adds a new pillar to its R&D and commercial plans. Roche Holding, trading at around CHF322.7, is entering this alliance from...

SoftwareOne Holding (SWX:SWON) laid out its 2030 financial targets after acquiring Crayon, telling investors it aims for an EBITDA margin above 28% and free cash flow conversion above 60% over the cycle. See our latest analysis for SoftwareOne Holding. The CHF8.76 share price has been supported by a 24.01% 1 month share price return and a 26.70% 3 month share price return. However, year to date the share price is down 2.94%, and the 5 year total shareholder return is down 54.21%. Recent...

Why Dottikon ES Holding’s Latest Earnings Matter for Investors Dottikon ES Holding (SWX:DESN) has drawn fresh attention after reporting full year results to March 31, 2026, with higher sales of CHF 428.44 million, alongside slightly lower net income and earnings per share. See our latest analysis for Dottikon ES Holding. The latest results arrived after a weaker share price patch, with the stock down 19% on a 30 day share price return and 17.98% on a year to date share price return. Even so,...

Logitech International (SWX:LOGN) has introduced its Signature Comfort Plus series, a new line of mice and keyboard combos focused on comfort, multi device productivity, enterprise deployment, environmentally friendly materials, and battery life. See our latest analysis for Logitech International. At a share price of CHF91.26, Logitech has seen a 30 day share price return of 8.26% and a 90 day share price return of 27.96%, while the 1 year total shareholder return of 31.70% contrasts with a 5...

Compagnie Financière Tradition (SWX:CFT) is back on investors’ radar after a recent share move, which has coincided with fresh interest in how its earnings profile and valuation currently stack up. See our latest analysis for Compagnie Financière Tradition. Recent trading reflects that tension between growth and valuation, with the share price at CHF282.0 after a 7 day share price return of 5.2% but a 30 day share price return that is down 5.2%. At the same time, the 1 year total shareholder...

Novartis (SWX:NOVN) is back in focus after releasing late stage trial results for Cosentyx in polymyalgia rheumatica and Vanrafia in IgA nephropathy, with both programs showing statistically significant efficacy and supportive safety data. See our latest analysis for Novartis. These late stage results for Cosentyx, Vanrafia, Scemblix and Pluvicto arrive as Novartis trades at CHF117.98, with a 1 month share price return of 4.08% and a 1 year total shareholder return of 25.23%. This suggests...

In recent weeks, Partners Group Holding capped withdrawals on an US$8.6 billion evergreen private equity fund after investor redemption requests exceeded its 5% quarterly limit, joining other private-credit players in tightening liquidity to protect long-term investors. The move underscores how the rapid growth of semi-liquid private-market products can expose firms like Partners Group to shifts in individual investor sentiment and liquidity needs. Next, we’ll examine how Partners Group’s...

In recent weeks, Roche and its subsidiaries reported a series of developments, including FDA approval of FoundationOne CDx as a companion diagnostic for Genentech’s Itovebi regimen in PIK3CA‑mutated HR‑positive, HER2‑negative breast cancer, US FDA Priority Review acceptance for oral SERD giredestrant in early ER‑positive, HER2‑negative breast cancer, advancing Phase II/III obesity candidates enicepatide and petrelintide, and launching an AI‑enabled Liver Disease Panel in Europe alongside a...

Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...

In recent days, Novartis reported Phase III data showing that Vanrafia slowed kidney function decline in IgA nephropathy and Cosentyx improved sustained remission and reduced steroid use in polymyalgia rheumatica, with results published and presented at major medical congresses. Together, these late-stage readouts highlight Novartis’s push to expand existing franchises into specialty kidney and rheumatology indications where treatment options are limited. Next, we’ll examine how Cosentyx’s...

As European markets navigate the complexities of geopolitical developments and economic adjustments, the pan-European STOXX Europe 600 Index shows modest gains, reflecting investor optimism amid global uncertainties. With this backdrop, dividend stocks in Europe present a compelling opportunity for investors seeking stable income streams; these stocks are often characterized by strong fundamentals and consistent payout histories that can provide resilience in fluctuating market conditions.

ABB (SWX:ABBN) has integrated its power systems as SimReady 3D digital assets into NVIDIA's Omniverse DSX Blueprint. The partnership focuses on virtual modeling, validation, and optimization of data center power distribution for AI workloads before facilities are built. The announcement extends ABB's digital twin and AI infrastructure offering for large scale, energy focused data centers. ABB comes into this announcement with the share price at CHF86.1 and very strong recent returns,...

As European markets show cautious optimism amid geopolitical developments and economic adjustments, investors are increasingly focused on identifying growth opportunities with strong fundamentals. In this context, companies with high insider ownership often attract attention as they may indicate a strong alignment of interests between management and shareholders, potentially offering resilience in uncertain market conditions.